Overview
- For 2025, CVS now expects at least $400 billion in revenue, GAAP operating income of $4.37 billion to $4.54 billion, adjusted operating income of $14.22 billion to $14.39 billion, GAAP diluted EPS of a $0.32 to $0.22 loss, and adjusted EPS of $6.60 to $6.70, with cash flow from operations of $7.5 billion to $8 billion.
- The 2026 outlook calls for at least $400 billion in revenue, GAAP operating income of $13.26 billion to $13.60 billion, and adjusted EPS of $7.00 to $7.20, with CFO Brian Newman saying the company is closing out 2025 with meaningful momentum.
- CVS introduced an AI-native consumer engagement platform anchored in a single app designed to integrate services across Aetna, Caremark, retail pharmacy and external partners to simplify navigation, personalize care, lower costs and improve outcomes.
- Management committed to a mid-teens adjusted EPS compound annual growth rate through 2028, driven by Aetna margin recovery, wins and margin performance at Caremark, stable pharmacy earnings and a path to profitability for healthcare delivery.
- The company emphasized national scale, citing reach to about 185 million consumers, more than 9,000 pharmacies, 1.5 million provider relationships and a footprint placing roughly 85% of Americans within 10 miles of a CVS Pharmacy.